Q-omics provides the consensus-scored CICP16 profile across patient tissues and cancer cell-line models. CICP16 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CICP16 is differentially expressed in 6, with the highest sampling consensus in THCA. Additionally, CICP16 RNA expression shows 19,618 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, THCA, and THYM as cancer lineages where CICP16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CICP16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CICP16 survival associations across molecular data types. CICP16 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CICP16 RNA expression–survival associations across cancer types. High CICP16 expression shows unfavorable associations in THCA, LUSC, CESC and UCEC, but favorable associations in HNSC and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for CICP16 RNA expression.
This table summarizes CICP16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CICP16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CICP16 shows lower tumor expression in THCA, KICH, LUSC and COAD and higher tumor expression in READ and CHOL. The THCA box plot shows higher CICP16 RNA expression in normal versus tumor tissue (log2 FC = −0.314, t-test p < 0.001).
This table shows molecular features associated with CICP16 in patient tissues and cancer cell lines. In patient samples, CICP16 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
